Aetna gets antitrust suit moved back to state court
American health care company Aetna has convinced a California court to transfer its antitrust action claiming that Gilead and other drugmakers used pay-for-delay tactics to maintain high costs of HIV treatments.
Novartis Hepatitis C patent upheld by Delhi High Court
In a victory for Novartis, the Delhi High Court in India has issued a permanent injunction against two India-based companies which had allegedly sought to make a generic version of the Hepatitis C treatment, Revolade.
11th circ ‘eviscerated’ orphan drug rights, says petition
New Jersey pharma company Jacobus Pharmaceutical has asked the US Supreme Court to review an 11th Circuit verdict that it claims “eviscerated” decades of precedent regarding Orphan Drug Act exclusivity.
BMS sues MSN over Pomalyst generic
Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.
MSD targets Mankind’s diabetes generic in patent suit
Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.
Roche asks court for halt of Novartis unit’s generic launch
Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.
Gilead loses bid to quash parallel antitrust HIV lawsuit
Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.
MSD, Pfizer try to stop three Steglatro generics
Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.
Campaigners ask US govt to force down prices for common drugs
Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.
Novo Nordisk and Sandoz settle Victoza patent suit
Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.